Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).

Journal: The Journal of molecular diagnostics : JMD
PMID:

Abstract

Cancers of unknown primary (CUP) are metastatic cancers for which the primary tumor is not found despite thorough diagnostic investigations. Multiple molecular assays have been proposed to identify the tissue of origin (TOO) and inform clinical care; however, none has been able to combine accuracy, interpretability, and easy access for routine use. We developed a classifier tool based on the training of a variational autoencoder to predict tissue of origin based on RNA-sequencing data. We used as training data 20,918 samples corresponding to 94 different categories, including 39 cancer types and 55 normal tissues. The TransCUPtomics classifier was applied to a retrospective cohort of 37 CUP patients and 11 prospective patients. TransCUPtomics exhibited an overall accuracy of 96% on reference data for TOO prediction. The TOO could be identified in 38 (79%) of 48 CUP patients. Eight of 11 prospective CUP patients (73%) could receive first-line therapy guided by TransCUPtomics prediction, with responses observed in most patients. The variational autoencoder added further utility by enabling prediction interpretability, and diagnostic predictions could be matched to detection of gene fusions and expressed variants. TransCUPtomics confidently predicted TOO for CUP and enabled tailored treatments leading to significant clinical responses. The interpretability of our approach is a powerful addition to improve the management of CUP patients.

Authors

  • Julien Vibert
    INSERM U830, Équipe Labellisée Ligue Nationale Contre le Cancer, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France.
  • Gaëlle Pierron
    Somatic Genetics Unit, Department of Genetics, Institut Curie Hospital, Paris, France.
  • Camille Benoist
    Clinical Bioinformatic Unit, Department of Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France.
  • Nadège Gruel
    INSERM U830, Équipe Labellisée Ligue Nationale Contre le Cancer, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France.
  • Delphine Guillemot
    Somatic Genetics Unit, Department of Genetics, Institut Curie Hospital, Paris, France.
  • Anne Vincent-Salomon
    Department of Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France.
  • Christophe Le Tourneau
    Department of Drug Development and Innovation, INSERM U900, Paris-Saclay University, Institut Curie Hospital and Research Center, Paris and Saint-Cloud.
  • Alain Livartowski
    Department of Medical Oncology, Institut Curie Hospital, Paris, France.
  • Odette Mariani
    Department of Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France.
  • Sylvain Baulande
    Institut Curie Genomics of Excellence (ICGex) Platform, PSL Research University, Institut Curie Research Center, Paris, France.
  • François-Clément Bidard
    Department of Medical Oncology, Institut Curie Hospital, Paris, France; INSERM CIC-BT 1428, UVSQ, Paris-Saclay University, Saint-Cloud, France.
  • Olivier Delattre
    INSERM U830, Équipe Labellisée Ligue Nationale Contre le Cancer, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France; Somatic Genetics Unit, Department of Genetics, Institut Curie Hospital, Paris, France.
  • Joshua J Waterfall
    Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France; INSERM U830, PSL Research University, Institut Curie Research Center, Paris, France.
  • Sarah Watson
    INSERM U830, Équipe Labellisée Ligue Nationale Contre le Cancer, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France; Department of Medical Oncology, Institut Curie Hospital, Paris, France. Electronic address: sarah.watson@curie.fr.